While Las Vegas Sands shares have struggled to keep pace with the broader market, a majority of Wall Street analysts maintain a constructive outlook, betting on a recovery in Macau and the company's long-term integrated resort model.
Finnish cargo handling giant Kalmar Oyj partners with Tata Consultancy Services to build an AI-powered digital core, aiming to boost operational efficiency and solidify its long-term service offerings in the global ports sector.
As sports betting handles hit record highs, data reveals a stark contrast: the average bettor consistently loses, while disciplined investing in instruments like index funds builds wealth over time.
Shareholders in Harley-Davidson's electric motorcycle spinoff, LiveWire Group, have seen their holdings erode dramatically over five years, with a recent $55 million weekly loss adding to the pain. The company's ongoing revenue contraction raises fundamental questions about its path to profitability in the competitive EV market.
A new report shows a 21% year-over-year decline in healthcare bankruptcy filings, offering a glimmer of relief. However, experts warn that deep-seated pressures from Medicaid cuts, policy shifts, and rising operational costs threaten to undermine the sector's fragile stability in the coming years.
Hess Midstream Partners LP (HESM) signals a pivotal shift towards robust free cash flow generation, forecasting a 40% drop in capital expenditures for 2026 as its core system build-out concludes. Despite near-term weather headwinds, strong minimum volume commitments underpin financial targets through 2028.
A sharp reversal in gold and silver prices, coupled with a slide in Bitcoin and Asian equities, rattled investors at the start of February, raising questions about the sustainability of recent market rallies.
As United Parcel Service executes a strategic overhaul focused on profitability over volume, its financials reveal a nascent but promising trend, leading some investors to see a potential rebound on the horizon despite recent stock declines.
A volatile January has underscored a stark shift for investors: political shocks emanating from Washington now pose a greater threat to portfolios than traditional economic or earnings concerns, reshaping risk calculus across global markets.
Alibaba Group is making a massive, multi-billion yuan bet to integrate its Qwen AI assistant across its ecosystem and develop its own AI chips, signaling a strategic pivot to reduce foreign dependency and deepen user engagement amid intense competition.
Apple's acquisition of Israeli AI audio startup Q.ai signals a deeper push into biometric wearables, as the tech giant reportedly reshuffles its 2026 roadmap to prioritize premium iPhones—including a long-rumored foldable model—while navigating ongoing component shortages.
Floor & Decor Holdings (FND) shares have retreated over 7% this week, sparking debate among investors. While the home improvement retailer posts solid revenue of $4.66 billion, its premium valuation and aggressive expansion plans face a cooling housing market test.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
The all-stock deal creates one of the nation's largest independent oil and gas producers, headquartered in Houston, with combined assets poised to reshape the competitive landscape of the shale sector.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
